QQ客服 官方微博 反馈留言

	Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
	Domchek, Susan M.; Robson, Mark; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Masuda, Norikazu; Delaloge, Suzette; Li, Wei; Armstrong, Anne; Conte, Pierfranco
	2018
卷号	78期号:4
ISSN号	0008-5472
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6360477
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Domchek, Susan M.,Robson, Mark,Im, Seock-Ah,et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD[J],2018,78(4).
APA	Domchek, Susan M..,Robson, Mark.,Im, Seock-Ah.,Senkus, Elzbieta.,Xu, Binghe.,...&Tung, Nadine.(2018).Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD.,78(4).
MLA	Domchek, Susan M.,et al."Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD".78.4(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。